Search

Simple Summary: Chronological aging has long been considered an immutable risk factor for cerebral small vessel disease, but recent studies have revealed the potential for biological aging to be modulated and possibly even slowed or reversed, offering a promising avenue for intervention. Emerging studies have reported that biological aging biomarkers, such as leukocyte telomere length and epigenetic clocks, are associated with the risk of cerebral small vessel disease. However, the results remain inconsistent and controversial. Hence, in this study, we sought to explicate the underlying causal relationship between biomarkers of aging and cerebral small vessel disease. The results show that genetically determined leukocyte telomere length and epigenetic clocks were not associated with the ten measures of cerebral small vessel disease. Our study did not provide evidence to support a causal association between cerebral small vessel disease and the aging biomarkers of leukocyte telomere length and epigenetic clocks; thus, more studies are needed to evaluate the potential of reverse-biological-aging therapy in cerebral small vessel disease. Biological aging biomarkers, such as leukocyte telomere length (LTL) and epigenetic clocks, have been associated with the risk of cerebral small vessel disease (CSVD) in several observational studies. However, it is unclear whether LTL or epigenetic clocks play causal roles as prognostic biomarkers in the development of CSVD. We performed a Mendelian randomization (MR) study of LTL and four epigenetic clocks on ten subclinical and clinical CSVD measures. We obtained genome-wide association (GWAS) data for LTL from the UK Biobank (N = 472,174). Data on epigenetic clocks were derived from a meta-analysis (N = 34,710), and CSVD data (N cases =1293–18,381; N controls = 25,806–105,974) were extracted from the Cerebrovascular Disease Knowledge Portal. We found that genetically determined LTL and epigenetic clocks were not individually associated with ten measures of CSVD (IVW p > 0.05), and this result was consistent across sensitivity analyses. Our findings imply that LTL and epigenetic clocks may not help in predicting CSVD development as causal prognostic biomarkers. Further studies are needed to illustrate the potential of reverse biological aging in serving as an effective form of preventive therapy for CSVD. [ABSTRACT FROM AUTHOR]

This letter to the editor discusses the successful treatment of a 16-year-old boy with concurrent vitiligo and atopic dermatitis using the JAK inhibitor upadacitinib. The article explains that vitiligo is a depigmentation disorder caused by the destruction of melanocytes, and atopic dermatitis is characterized by a type 2 immune response. The authors suggest that there may be a potential association between vitiligo and atopic dermatitis due to overlapping genetic and immune mechanisms. The patient in the case study experienced repigmentation and relief from symptoms after treatment with upadacitinib. The authors conclude that upadacitinib can be an effective treatment option for patients with both vitiligo and atopic dermatitis. [Extracted from the article]

Guided bone regeneration (GBR) technology is the most widely used and stable method for bone defect repair. However, infectious bone defect limits the application of this technique. Herein, a small intestinal submucosa (SIS) membrane modified by chimeric peptides as a new type of GBR membrane is developed for efficacious tissue regeneration. Based on the main components of SIS membrane are I and III collagen, collagen binding peptides TKKTLRT and KELNLVY sequences are used to construct chimeric peptides with healing‐promoting peptide Hst1 or antibacterial osteogenic peptide JH8194, so as to realize the specifically target of SIS. This method achieves the fast and efficient multifunctional modification of SIS membrane. The chimeric peptides modified SIS (pSIS) membrane has satisfactory biocompatibility and a certain degree of antibacterial activity. Moreover, pSIS promotes the osteogenic related factors expression of rat bone mesenchymal stem cells and demonstrates great bone regeneration in rat skull defect model. Furthermore, pSIS accelerates the migration of oral epithelial cells in vitro and activate integrin α3β1 signal pathway contribute to wound healing. This study presents a novel biomaterial design of GBR membrane, specifically for the treatment of infectious bone defects. [ABSTRACT FROM AUTHOR]

The guided bone regeneration (GBR) technique is the most common and durable approach to repairing bone defects in periodontal surgery. However, membrane exposure causes bacterial infiltration, which lowers the functional integrity of the barrier membrane and destroys bone repair. Here, an antibacterial peptide-modified small intestinal submucosa (SIS) membrane is used as a new GBR membrane for effective bone regeneration. The peptide JH8194 was placed into chitosan microspheres to preserve its stability and allow for sustained release, which realizes rapid and efficient functional modification of the SIS membrane. Biocompatibility and certain antibacterial activities were found in the modified SIS membrane (SIS@CS-JH8194). Additionally, in vitro experiments showed that SIS@CS-JH8194 promoted the expression of osteogenic-related factors and decreased the secretion of inflammatory factors in rat bone mesenchymal stem cells. In vivo experiments showed that SIS@CS-JH8194 could effectively promote bone regeneration in rat skull defects. In this work, we created a new antibacterial GBR membrane to help avoid postoperative infection and improve bone tissue regeneration. [ABSTRACT FROM AUTHOR]

Guided bone regeneration (GBR) is a promising strategy for repairing bone defects using bioactive membranes. In this study, a new type of GBR membrane based on the small intestinal submucosa (SIS) was created, and its surface structure, cytological characteristics, and bone defect repair ability were compared with commonly used membranes. Our results show that compared to the Heal-all and Dentium membranes, the SIS membrane has an asymmetric structure that does not affect the proliferation of bone marrow mesenchymal stem cells (BMSCs). Instead, it increased their formation of calcium nodules and expression of bone morphogenetic protein-2 (BMP-2), alkaline phosphatase (ALP), runt-related transcription factor 2 (Runx2), and osteopontin (OPN). Six weeks after their insertion into a rat calvarial defect model, increased bone growth was observed in the SIS membrane group. Our results indicate that the SIS membrane has good biocompatibility and is more effective in promoting early bone formation than existing membranes. Given the wide range of source materials and simple preparation processes available, SIS membrane is a promising candidate for guided bone regeneration. [ABSTRACT FROM AUTHOR]

Guided bone regeneration (GBR) technology is an effective method for reconstructing bone defects, and barrier membranes are widely used in this process. The objective of this study was to develop a novel asymmetric SIS (small intestinal submucosa) membrane and modify the membrane with exosomes and engineered recombinant peptides. The asymmetric SIS membrane was developed with liquid nitrogen quencher. The engineered recombinant peptides were designed by connecting collagen binding peptides with the exosomal capture peptide CP05 via linker. In vitro experiments demonstrated that the engineered recombinant peptides contributed to promoting the positive effect of exosomes on the osteogenic differentiation of BMSCs. Further mechanistic studies confirmed that the PI3K/Akt signaling pathway is critical in the exosome-induced osteogenic differentiation of BMSCs. Moreover, the asymmetric SIS membrane combining engineered recombinant peptides and exosomes could reconstruct bone defects effectively within 12 weeks. Therefore, the membrane developed in this study has the potential to repair bone defects. • The asymmetric SIS membrane was developed using liquid nitrogen quencher. • Engineered recombinant peptides were designed by connecting collagen binding peptides with CP05. • SIS–P1P2-EXO membranes could reconstruct bone defects effectively within 12 weeks. [ABSTRACT FROM AUTHOR]